Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
If you don't like the approach/strategy, sell up and leave the board
There aren't any material short positions on RR
https://shorttracker.co.uk/company/GB00B63H8491/
And this part:
The outsourced manufacturer of Fruitflow II SD (Fruitflow in spray dried powder form, the primary form of Fruitflow which is sold) is currently running some long-term stability tests on the product, with a possible view to an extension to the product's existing approved shelf life, and the results of these tests are expected in the coming weeks.
Since this statement................when are we going to learn more? Surely it's imperative we are updated on sales/cash position, when they advised it was so critical
The Company will be in a better position to judge how best to manage its future inventory requirements (which can be met from either: (i) DSM's existing Fruitflow inventory; or (ii) a new Fruitflow production run) in the coming weeks once it has a clearer picture of: (i) the likely demand from the Company's actual and prospective Fruitflow customers for the next 12 months and beyond, to include By-Health; and (ii) the outcome of the stability tests on the existing Fruitflow inventory. The Company is therefore currently seeking to negotiate an extension to the initial three month inventory handover period with DSM. While these negotiations progress the Company will receive incoming funds from further sales of the Company's existing Fruitflow inventory.
The Company remains in negotiations with a third party which might be able to hold inventory for the Company on a consignment basis, with the Company potentially only paying for the inventory when it is required for sale.
Based on the Company's current level of cash it continues to be expected that the Group will need to raise further equity finance, or potentially new loan finance, in the coming months. Considering the success of previous fundraisings and the current performance of the business, the Directors continue to have a reasonable expectation of raising sufficient additional equity capital or new loan finance.
I expect a lot of the warrants are getting executed, which has subdued the SP somewhat. Anyway of finding out?
The warrants covered by the block listing have exercise prices of £0.10, £0.12, £0.20, and £0.25 per share. If exercised in full, the total receipts due to the Company would be approximately £7.2million, corresponding to a weighted average exercise price of £0.22 per share.
Ok, let's clear up 2 things here please.
Firstly, if that was a quote from the 2022 results, why the large number of trades and SP movement late on today?
Secondly, that HMRC case is against Perenco for some fields they acquired from BP in North Sea. Absolutely nothing to do with Bowleven
Where's this quote from?
Nice to hear, I nearly cut my losses here (had £9k at 30p), but hanging around in desperate hope of recouping something
JP - someone who has been a member of this site since March 23 and who's entire posting history has been on this one share. No agenda at all I'm sure..............#paidramper
Thanks for sharing, very interesting. This certainly explained Ali's focus on it:
AI is not new in drugmaking. Biotech firms have been tinkering with it for years. Now interest from big pharma is growing. Last year Emma Walmsley, chief executive of GSK, said it could improve the productivity of research and development, the industry’s most profound challenge. Moderna recently described itself as “laser-focused” on AI. Sanofi is “all in”. Morgan Stanley, an investment bank, reckons that within a decade the pharmaceutical industry may be spending $50bn a year on AI to speed up drug development.
He did reference 'putting the accelerator down' and dodged the question on commercial deals and whether additional funding would be required, so I wouldn't be surprised if that did materialise.
Regardless, I am certainly more positive about the prospects following the call. It seems they've got the bit between the teeth and are looking to grasp the computational genetic AI opportunity
Did anyone catch the Investor Meet?
Very interesting, Ali clearly expects this to be a 'multi-billion' pound company
The SP is where I would expect. The company is losing £15m a year and will likely require additional funds in the next 12-18 months. Strategic investment is a possibility, as opposed to discounted fund raise. The other drag is uncertainty over the delivery and success of Mistral. Steady away but I will wait for the SP to drop into the mid 30s before I top up. Potential is huge here, but it's also worth bearing in mind that this is an £81m MCAP company, currently losing £15-20m a year (obviously that will change soon enough). People are wary of jam tomorrow companies, particularly in the current climate. Just look at SCE
Not quite true. Most airlines hedge a higher proportion of their fuel than 60%. Typically between 2/3s and 75% but can be higher. I would say 70-75% is a reasonable estimate.
Fuel accounts for about 1/3 of costs, so the impact is 25% of a 1/3. So variances in the daily fuel price has an impact on c.8% of Wizz Air's costs. Not insignificant but also not significant for the daily changes in oil price to have a material impact
Had a huge drop yesterday on no apparent reason?
PS: Are Tesla car batteries versus Invinity scale grid storage batteries not 'comparing apples and pears' ?
Yes, which is why noone is comparing them (other than you).
Tesla's Megapack is the comparison